Cover Image
市場調查報告書

化膿性汗腺炎 : 開發平台分析

Hidradenitis Suppurativa - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 229796
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
化膿性汗腺炎 : 開發平台分析 Hidradenitis Suppurativa - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 97 Pages
簡介

化膿性汗腺炎,是所謂皮膚下出現粒狀或小石狀朣包等慢性皮膚疾病。尤其常發於皮膚容易產生摩擦的地方(腋下、鼠鼷部、臀部之間、乳房下方等)會頑強地頻發朣包,為其特徵。

本報告提供全球各國治療化膿性汗腺炎用的開發中產品開發情形相關分析、彙整開發中產品的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介、主要藥物概要(產品概要、功能機制、研究開發(R&D)進展狀況)、最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

化膿性汗腺炎概要

化膿性汗腺炎的開發

  • 化膿性汗腺炎開發中產品:概要
  • 化膿性汗腺炎開發中產品:比較分析

各企業開發中的化膿性汗腺炎治療藥

大學/研究機關研究中的化膿性汗腺炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

化膿性汗腺炎治療藥:開發中的產品一覽(各企業)

化膿性汗腺炎治療藥:研究中的產品一覽(大學/研究機關)

化膿性汗腺炎開發治療藥的企業

  • AbbVie Inc.
  • Cellceutix Corporation
  • Delenex Therapeutics AG
  • Johnson & Johnson
  • Novartis AG

化膿性汗腺炎:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • adalimumab
  • adalimumab 生技仿製藥
  • CJM-112
  • DLX-105
  • DLX-2751
  • 化膿性汗腺炎細胞薄膜破壞小分子
  • ustekinumab

化膿性汗腺炎治療藥:最新的藥物簡介

暫停中的計劃

開發中止的產品

化膿性汗腺炎相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9517IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa - Pipeline Review, H2 2017, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 1, 5, 1 and 1 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Hidradenitis Suppurativa - Overview
  • Hidradenitis Suppurativa - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Hidradenitis Suppurativa - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hidradenitis Suppurativa - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Celgene Corp
  • Coherus BioSciences Inc
  • Immunwork Inc
  • InflaRx GmbH
  • Innovation Pharmaceuticals Inc
  • Novartis AG
  • Panacea Biotec Ltd
  • Sandoz International GmbH
  • XBiotech Inc
  • Hidradenitis Suppurativa - Drug Profiles
  • adalimumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • adalimumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • adalimumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • adalimumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • adalimumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • adalimumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • adalimumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • adalimumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • apremilast - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • brilacidin tetrahydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CJM-112 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IFX-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TE-2232 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Xilonix - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hidradenitis Suppurativa - Dormant Projects
  • Hidradenitis Suppurativa - Discontinued Products
  • Hidradenitis Suppurativa - Product Development Milestones
  • Featured News & Press Releases
  • Jun 12, 2017: AbbVie's Humira accepted for use in NHS Scotland
  • Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application
  • Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa
  • Jan 04, 2017: InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa
  • Nov 14, 2016: AbbVie's HUMIRA (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
  • Sep 26, 2016: AbbVie To present New Data on HUMIRA (adalimumab) at the 25th European Academy of Dermatology and Venereology Congress
  • Aug 03, 2016: Clinical trial results support adalimumab treatment for painful skin condition
  • May 09, 2016: Scottish Medicines Consortium (SMC) accepts Humira (adalimumab) as the first approved treatment for the painful, chronic skin condition hidradenitis suppurativa for patients in Scotland
  • May 04, 2016: NICE recommends Humira (adalimumab) as the first approved treatment for skin condition hidradenitis suppurativa in England and Wales
  • Mar 02, 2016: Abbvie Announces New Dermatology Research From More Than 35 Presentations On Humira (Adalimumab), Long-Term And Real-World Data At The American Academy Of Dermatology 2016 Annual Meeting
  • Jan 06, 2016: AbbVie HUMIRA (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa
  • Oct 05, 2015: AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress
  • Sep 10, 2015: Abbvie's Humira (Adalimumab) Receives First And Only U.S. Food And Drug Administration Approval For Moderate To Severe Hidradenitis Suppurativa
  • Jul 30, 2015: Humira (Adalimumab) Approved By European Commission For Moderate To Severe Hidradenitis Suppurativa
  • Jun 26, 2015: Abbvie's Humira (Adalimumab) Receives Positive Chmp Opinion To Treat Adult Patients With Active Moderate To Severe Hidradenitis Suppurativa, A Chronic Inflammatory Skin Disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hidradenitis Suppurativa, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Hidradenitis Suppurativa - Pipeline by AbbVie Inc, H2 2017
  • Hidradenitis Suppurativa - Pipeline by Celgene Corp, H2 2017
  • Hidradenitis Suppurativa - Pipeline by Coherus BioSciences Inc, H2 2017
  • Hidradenitis Suppurativa - Pipeline by Immunwork Inc, H2 2017
  • Hidradenitis Suppurativa - Pipeline by InflaRx GmbH, H2 2017
  • Hidradenitis Suppurativa - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
  • Hidradenitis Suppurativa - Pipeline by Novartis AG, H2 2017
  • Hidradenitis Suppurativa - Pipeline by Panacea Biotec Ltd, H2 2017
  • Hidradenitis Suppurativa - Pipeline by Sandoz International GmbH, H2 2017
  • Hidradenitis Suppurativa - Pipeline by XBiotech Inc, H2 2017
  • Hidradenitis Suppurativa - Dormant Projects, H2 2017
  • Hidradenitis Suppurativa - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Hidradenitis Suppurativa, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top